HRP20140380T1 - N-oksidni i/ili di-n-oksidni derivati stabilizatora/modulatora dopaminskog receptora koji pokazuju poboljšane profile kardiovaskularnih nuspojava - Google Patents

N-oksidni i/ili di-n-oksidni derivati stabilizatora/modulatora dopaminskog receptora koji pokazuju poboljšane profile kardiovaskularnih nuspojava Download PDF

Info

Publication number
HRP20140380T1
HRP20140380T1 HRP20140380AT HRP20140380T HRP20140380T1 HR P20140380 T1 HRP20140380 T1 HR P20140380T1 HR P20140380A T HRP20140380A T HR P20140380AT HR P20140380 T HRP20140380 T HR P20140380T HR P20140380 T1 HRP20140380 T1 HR P20140380T1
Authority
HR
Croatia
Prior art keywords
disorders
compound according
pharmaceutically acceptable
acceptable salt
iatrogenic
Prior art date
Application number
HRP20140380AT
Other languages
English (en)
Croatian (hr)
Inventor
Hakan V. Wikström
Original Assignee
IVAX International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IVAX International GmbH filed Critical IVAX International GmbH
Publication of HRP20140380T1 publication Critical patent/HRP20140380T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20140380AT 2007-04-12 2008-04-11 N-oksidni i/ili di-n-oksidni derivati stabilizatora/modulatora dopaminskog receptora koji pokazuju poboljšane profile kardiovaskularnih nuspojava HRP20140380T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700893 2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en) 2007-04-12 2008-04-11 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (1)

Publication Number Publication Date
HRP20140380T1 true HRP20140380T1 (hr) 2014-08-15

Family

ID=39864178

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140380AT HRP20140380T1 (hr) 2007-04-12 2008-04-11 N-oksidni i/ili di-n-oksidni derivati stabilizatora/modulatora dopaminskog receptora koji pokazuju poboljšane profile kardiovaskularnih nuspojava

Country Status (19)

Country Link
US (1) US9139525B2 (enExample)
EP (1) EP2146961B1 (enExample)
JP (1) JP5393654B2 (enExample)
CN (1) CN101711236B (enExample)
AU (1) AU2008239841B2 (enExample)
BR (1) BRPI0810161A2 (enExample)
CA (1) CA2683719C (enExample)
CY (1) CY1115337T1 (enExample)
DK (1) DK2146961T3 (enExample)
ES (1) ES2458592T3 (enExample)
HR (1) HRP20140380T1 (enExample)
IL (1) IL201401A (enExample)
MX (1) MX2009011020A (enExample)
NZ (1) NZ580856A (enExample)
PL (1) PL2146961T3 (enExample)
PT (1) PT2146961E (enExample)
RU (1) RU2470013C2 (enExample)
SI (1) SI2146961T1 (enExample)
WO (1) WO2008127188A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
JP5716202B2 (ja) 2008-11-24 2015-05-13 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての3−フェニル−3−メトキシピロリジン誘導体
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2012028635A1 (en) 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
DK3010506T3 (da) 2013-06-21 2021-07-12 Prilenia Neurotherapeutics Ltd Pridopidin i behandling af huntingtons sygdom
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
DK3504187T3 (da) 2016-08-24 2025-04-14 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af funktionel tilbagegang
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
BR112019015000A2 (pt) 2017-01-20 2020-04-07 Prilenia Neurotherapeutics Ltd. uso de pridopidina para o tratamento da síndrome do x frágil
AU2018317346B2 (en) 2017-08-14 2021-08-26 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
CN111278431A (zh) 2017-08-30 2020-06-12 普瑞尼亚神经治疗有限公司 普利多匹定的高浓度剂型
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
AU2020218158B2 (en) 2019-02-04 2023-08-03 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1217296A (en) 1917-01-11 1917-02-27 Lewis A Peckham Shock-absorber.
US2813098A (en) 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US2813097A (en) 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US3131185A (en) 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (enExample) 1962-10-10
CH481123A (de) 1966-09-21 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ATE201669T1 (de) * 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
JPH06509069A (ja) 1991-06-27 1994-10-13 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンドおよびその用途
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
DE69912635T2 (de) 1998-11-23 2004-05-13 Sepracor Inc., Marlborough Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
NZ552411A (en) 2004-06-08 2010-04-30 Nsab Af Neurosearch Sweden Ab New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
MXPA06013941A (es) 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
JP2008509909A (ja) * 2004-08-11 2008-04-03 ウィリアムスバーグ・ホールディングス・エルエルシー 心毒性のない医薬化合物
PL1802573T3 (pl) 2004-10-13 2017-03-31 Teva Pharmaceuticals International Gmbh Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny
ATE417834T1 (de) * 2005-08-22 2009-01-15 Solvay Pharm Bv N-oxide als prodrugs von piperazin- und piperidinderivaten
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
AU2007247251B2 (en) 2006-05-02 2011-11-03 Solvay Pharmaceuticals B.V. N-oxides of pyridylmethylpiperazine and -piperidine derivatives
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130203886A1 (en) * 2010-03-05 2013-08-08 Nileshkumar Prakash Kukalyekar Process for the production of an uhmwpe article
WO2012028635A1 (en) 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
WO2014052933A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
US20140088145A1 (en) 2012-09-27 2014-03-27 Teva Pharmaceutical Industries, Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease

Also Published As

Publication number Publication date
DK2146961T3 (da) 2014-04-28
ES2458592T3 (es) 2014-05-06
US9139525B2 (en) 2015-09-22
PT2146961E (pt) 2014-04-30
AU2008239841A1 (en) 2008-10-23
JP2010523651A (ja) 2010-07-15
WO2008127188A1 (en) 2008-10-23
RU2009141300A (ru) 2011-05-20
MX2009011020A (es) 2009-10-30
PL2146961T3 (pl) 2014-09-30
CN101711236A (zh) 2010-05-19
US20100105736A1 (en) 2010-04-29
NZ580856A (en) 2011-11-25
CA2683719A1 (en) 2008-10-23
SI2146961T1 (sl) 2014-08-29
BRPI0810161A2 (pt) 2014-12-30
CA2683719C (en) 2015-07-14
AU2008239841B2 (en) 2013-07-18
EP2146961A4 (en) 2011-08-03
EP2146961B1 (en) 2014-01-29
RU2470013C2 (ru) 2012-12-20
JP5393654B2 (ja) 2014-01-22
IL201401A (en) 2015-10-29
CN101711236B (zh) 2012-10-31
IL201401A0 (en) 2010-05-31
EP2146961A1 (en) 2010-01-27
CY1115337T1 (el) 2017-01-04

Similar Documents

Publication Publication Date Title
JP2010523651A5 (enExample)
WO2008057862A3 (en) MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
JP2013512926A5 (enExample)
GEP20146029B (en) Organic compounds
ATE550337T1 (de) Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung
HRP20211272T1 (hr) 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda
WO2008112483A3 (en) Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
HRP20211282T1 (hr) Oksisteroli i postupci njihovog korištenja
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
EP2295422A3 (de) Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
RU2014145682A (ru) Органические соединения
RU2012127770A (ru) Полициклические соединения и способы их применения
TW200628154A (en) Organic compounds
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
MX2009011020A (es) Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
HRP20170570T1 (hr) Piperazin-1-il-trifluormetil-supstituirani-piridini kao brzo disocirajući antagonisti receptora dopamina 2
HRP20120913T1 (hr) Derivati 4-alkoksipiridazina kao brzo disocirajuä†i antagonisti dopamin 2 receptora
HRP20120876T1 (hr) Brzo disocirajuä†i antagonisti dopamin 2 receptora
MX2015014353A (es) Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina.
EA201170097A1 (ru) Замещенные трициклические производные против нейродегенеративных заболеваний
RU2016132574A (ru) Органические соединения
FI3625213T3 (fi) (+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt
TH127359A (th) อนุพันธ์ 1,2,4-ไตรอะโซโล[4,3-a]ไพริดีนและการใช้มันในฐานะโพสิทิฟ อัลโลสเตริก มอดูเลเตอร์ ของหน่วยรับความรู้สึก MGLUR2
HK1202116A1 (en) Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands